Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
Protara Therapeutics (Nasdaq: TARA) announced its participation in the TD Cowen 5th Annual Oncology Innovation Summit. The company, focused on developing transformative therapies for cancer and rare diseases, will have its management team engage in a virtual fireside chat on May 28, 2024, at 3:00 pm ET. This event will be available via live webcast through Protara's website and archived temporarily after the presentation.
- Protara Therapeutics will gain visibility by participating in a notable industry event.
- The virtual fireside chat provides a platform to discuss their cancer and rare disease therapies.
- Archiving the webcast allows for extended reach and engagement with stakeholders.
- No new financial data or clinical trial results were announced, which may be disappointing to investors looking for concrete updates.
- Participation in the event alone might not significantly impact stock performance without substantial news.
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit on Tuesday, May 28, 2024 at 3:00 pm ET.
A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
When is Protara Therapeutics presenting at the TD Cowen Oncology Innovation Summit?
How can I access Protara Therapeutics' presentation at the TD Cowen Oncology Innovation Summit?
Will the Protara Therapeutics webcast be available after the event?
What is the focus of Protara Therapeutics?
